Search results
Added:
3 months ago
Source:
Radcliffe Cardiology
A new study published in JACC has evaluated the prevalence and prognostic significance of secondary tricuspid regurgitation (STR) across the spectrum of heart failure with preserved ejection fraction (HFpEF), finding that its presence is strongly associated with pulmonary vascular disease (PVD) and that different mechanisms of STR carry distinct prognoses.¹˒²This observational study analysed data…
View more
Timing of Heart Transplantation & LVADs
Video Series
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: Jordan Rance; Special Editor: Greg GuilloryA new analysis sheds light on the timing of protection offered by SGLT2 inhibitors. Researchers conducted a cross-trial analysis using individual participant data from four large-scale randomized clinical trials: CANVAS (type 2 diabetes with high atherosclerotic risk, NCT01032629), CREDENCE (diabetic kidney disease, NCT02065791), DAPA-HF (heart…
View more
ESC HFA 25: SCD-PROTECT
Author(s):
Johann Bauersachs
Added:
11 months ago
Video
Timing of Heart Transplantation & LVADs
Author(s):
Espeed Khoshbin, Owais Dar,
Start date:
Nov 05, 2024
Broadcast
Iron Deficiency in LVAD Patients
Author(s):
William Herrik Nielsen
,
Finn Gustafsson
Added:
1 year ago
Review Article
Author(s):
Clara Bonanad Lozano
,
Anjay Rastogi
Added:
1 year ago
Dr Anjay Rastogi (David Geffen School of Medicine UCLA, US) and Dr Clara Bonanad (University Clinical Hospital of Valencia, ES) discuss the evolving management strategies of hyperkalaemia in heart failure and chronic kidney disease, in this short video series. In this three part discussion they cover the most recent guidelines from ACC, ESC and KDIGO, real-world evidence from the recent ZORA…
View more
Author(s):
Mikhail Kosiborod
Added:
2 years ago
ACC.24 — We are joined onsite by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss the findings from the STEP HFpEF DM Trial (NCT04916470).The STEP HFpEF DM study aimed to investigate the effect of taking semaglutide 2.4mg once weekly in patients with heart failure with preserved ejection fraction (HFpEF) and diabetes mellitus type 2. The study looked at the impact of…
View more
Author(s):
Anastasia Shchendrygina
,
Amin Yehya
,
Hadi Skouri
Added:
9 months ago